Janssen's Stelara (ustekinumab) Receives the US FDA's Approval for the Treatment of Active Psoriatic Arthritis in Pediatric Patien...
August 2, 2022
Janssen Presents P-Ib/II (CHRYSALIS-2) Study Results of Rybrevant (amivantamab-vmjw) for Non-Small Cell Lung Cancer and EGFR Mutat...
July 27, 2022
PharmaShots Interview: Daphne Chan, Head of Dermatology Medical Affairs at Janssen Shares Insights on Clinical Study in Dermatolog...
July 26, 2022
Janssen Presents New and Updated Results of Imbruvica (ibrutinib) in P-II (CAPTIVATE) Study as Fixed-Duration Combination Regimen...
June 13, 2022
Janssen Reports Results of Tremfya (guselkumab) in P-III Studies Demonstrated Durable Efficacy Across Joint and Axial Symptoms for...
June 1, 2022
Janssen Presents Results of Tremfya (guselkumab) in P-II (GALAXI 1) Trial and Long-Term Safety Profile for Stelara (ustekinumab) t...
May 25, 2022
No more records!
Incisive News in 3 Shots.
First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
Terms of Service
Copyright © 2022 PharmaShots - All Rights Reserved.